Hengrui Medicine: Application for approval of the new indication for Rucaritumab Monoclonal Antibody for injection has been accepted and included in the priority review process.

Hengrui Pharmaceuticals announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received the "acceptance notice" issued by the National Medical Products Administration for the listing application of injection of Rucantruximab for the treatment of locally advanced or metastatic HER2-positive adult breast cancer patients who have previously received one or more anti-HER2 drugs. The application has been accepted by the National Medical Products Administration and has been included in the priority review process.